MedPath

A multi-centre, double-blind, placebo-controlled, multiple-dose crossover proof of concept study to compare the efficacy of mefenamic acid administered vaginally and orally in healthy menstruating women with primary dysmenorrhoea requiring analgesia

Not Applicable
Completed
Conditions
Primary dysmenorrhoea
Urological and Genital Diseases
Dysmenorrhoea
Registration Number
ISRCTN32847177
Lead Sponsor
Plethora Solutions Limited (UK)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
105
Inclusion Criteria

1. Healthy menstruating female with a history of primary dysmenorrhoea
2. Menstrual-related pain with cramping for which she requires the use of analgesics during each cycle
3. Regular menstrual cycles
4. Routinely uses intra-vaginal tampons and is able to use tampons without an applicator
5. Aged 18 to 40 years inclusive
6. No clinically significant medical history and normal clinical examination other than the underlying pathology requiring treatment, in the opinion of the Investigator
7. Able to understand and complete the rating scales
8. Provided written informed consent

Exclusion Criteria

A subject will be excluded from study participation if she meets any of the following criteria:
1. Has a history of, or known, hypersensitivity to mefenamic acid
2. Has a history of reactions such as asthma, urticaria, or allergic type reactions to other NSAIDs
3. Has received another investigational product within three months prior to screening
4. Is unwilling to avoid the use of any:
4.1. Opiate* within 24 hours
4.2. NSAID within 6 hours, or
4.3. Paracetamol within 4 hours, of starting study medication
5. Is pregnant, lactating, or is planning to become pregnant during the study
6. Is currently receiving or has received any hormonal contraception within the previous three months
7. Does not agree to use suitable non-hormonal contraception for the duration of the study
8. Has a history of Toxic Shock Syndrome (TSS)
9. Has a current untreated Sexually Transmitted Disease (STD) that could interfere with the study
10. Has, or has had, ulcerative, vesicular or papillomatous lesions of the cervix, vagina or genital area
11. Is known not to respond to mefenamic acid
12. Has signs or symptoms that contraindicate the administration of mefenamic acid
13. Has unresolved alcohol or drug abuse
14. Has severe menorrhagia which, in the opinion of the investigator, could interfere with the study
15. Is using complementary therapy, such as evening primrose oil, for the treatment of symptoms
16. Has any other condition which, in the opinion of the investigator, may interfere with the study

*Up to 16 mg codeine per dose (i.e., 2 co-codamol 8/500 mg tablets) is acceptable

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Menstrual-related pain intensity, recorded in a diary at baseline and a variety of timepoints over 24 hours
Secondary Outcome Measures
NameTimeMethod
Safety and tolerability of PSD508, measured over a period of 24 hours
© Copyright 2025. All Rights Reserved by MedPath